

Apostolia Maria Tsimberidou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8480145/publications.pdf>

Version: 2024-02-01

240
papers

13,694
citations

25034

57
h-index

26613

107
g-index

247
all docs

247
docs citations

247
times ranked

19505
citing authors

#	ARTICLE	IF	CITATIONS
1	Transcriptomics and solid tumors: The next frontier in precision cancer medicine. <i>Seminars in Cancer Biology</i> , 2022, 84, 50-59.	9.6	36
2	Innovative trial design in precision oncology. <i>Seminars in Cancer Biology</i> , 2022, 84, 284-292.	9.6	12
3	Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors. <i>Cancer Medicine</i> , 2022, 11, 340-347.	2.8	13
4	Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center. <i>Cancers</i> , 2022, 14, 1330.	3.7	0
5	AKT inhibition in the central nervous system induces signaling defects resulting in psychiatric symptomatology. <i>Cell and Bioscience</i> , 2022, 12, 56.	4.8	8
6	Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3108-3108.	1.6	0
7	Safety, pharmacokinetics, and clinical activity of OBI-3424, an AKR1C3-activated prodrug, in patients with advanced or metastatic solid tumors: A phase 1 dose-escalation study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3030-3030.	1.6	0
8	Effect of immunotherapy and time-of-day infusion chronomodulation on survival in advanced cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1588-1588.	1.6	4
9	First-in-human study of OBI-999: A globo H-targeting antibody-drug conjugate in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3029-3029.	1.6	1
10	Baseline predictors of hematological toxicity in patients with advanced cancer treated with ATR inhibitors in phase I/II clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3111-3111.	1.6	3
11	Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. <i>JCO Precision Oncology</i> , 2022, , .	3.0	15
12	Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with <i>BRAF</i>-mutated advanced cancers. <i>Cancer</i> , 2021, 127, 391-402.	4.1	6
13	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-~positive Metastatic Breast Cancer or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1247-1255.	7.0	5
14	Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110015.	3.2	6
15	Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. <i>Oncologist</i> , 2021, 26, 558-e1098.	3.7	18
16	Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. <i>British Journal of Cancer</i> , 2021, 124, 1533-1539.	6.4	20
17	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. <i>Npj Precision Oncology</i> , 2021, 5, 21.	5.4	12
18	Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. <i>Npj Precision Oncology</i> , 2021, 5, 33.	5.4	5

#	ARTICLE	IF	CITATIONS
19	Overview of Ocular Side Effects of Selinexor. <i>Oncologist</i> , 2021, 26, 619-623.	3.7	5
20	Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1634-1647.	6.3	28
21	T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 102.	17.0	64
22	Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. <i>Journal of Hematology and Oncology</i> , 2021, 14, 127.	17.0	12
23	Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. , 2020, 8, e000931.		11
24	Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Nonâ€‘small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 477-481.	2.6	7
25	Phase I study of imalumab (BAX69), a fully human recombinant antioxygenized macrophage migration inhibitory factor antibody in advanced solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1836-1848.	2.4	34
26	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. <i>Scientific Reports</i> , 2020, 10, 3080.	3.3	10
27	Phase 2 study of pembrolizumab in patients with advanced rare cancers. , 2020, 8, e000347.		95
28	Review of precision cancer medicine: Evolution of the treatment paradigm. <i>Cancer Treatment Reviews</i> , 2020, 86, 102019.	7.7	327
29	Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. <i>Experimental Hematology and Oncology</i> , 2020, 9, 7.	5.0	11
30	Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. <i>Oncotarget</i> , 2020, 11, 1-14.	1.8	1
31	Circulating tumor DNA analysis in the era of precision oncology. <i>Oncotarget</i> , 2020, 11, 188-211.	1.8	54
32	A nonparametric Bayesian basket trial design. <i>Biometrical Journal</i> , 2019, 61, 1160-1174.	1.0	7
33	Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	3.0	20
34	Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. <i>Journal of Clinical Oncology</i> , 2019, 37, 72-80.	1.6	17
35	Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. <i>Journal of Hematology and Oncology</i> , 2019, 12, 145.	17.0	35
36	Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancerâ€‘Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. <i>Cancers</i> , 2019, 11, 1987.	3.7	12

#	ARTICLE	IF	CITATIONS
37	Basket Trials and the MD Anderson Precision Medicine Clinical Trials Platform. Cancer Journal (Sudbury, Mass), 2019, 25, 282-286.	2.0	9
38	Defining, Identifying, and Understanding “Exceptional Responders” in Oncology Using the Tools of Precision Medicine. Cancer Journal (Sudbury, Mass), 2019, 25, 296-299.	2.0	6
39	Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies. British Journal of Clinical Pharmacology, 2019, 85, 530-539.	2.4	9
40	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer, 2019, 125, 463-472.	4.1	10
41	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Archives of Pathology and Laboratory Medicine, 2018, 142, 1242-1253.	2.5	120
42	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer, 2018, 120, 137-141.	2.0	29
43	Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Molecular Cancer Therapeutics, 2018, 17, 1595-1601.	4.1	30
44	Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits. Expert Opinion on Investigational Drugs, 2018, 27, 155-162.	4.1	28
45	Authors' Reply. Journal of Molecular Diagnostics, 2018, 20, 125-126.	2.8	1
46	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clinical Cancer Research, 2018, 24, 181-188.	7.0	127
47	Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Investigational New Drugs, 2018, 36, 416-423.	2.6	17
48	Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. Molecular Cancer Therapeutics, 2018, 17, 671-676.	4.1	33
49	Complete Response to a Fibroblast Growth Factor Receptor Inhibitor in a Patient With Head and Neck Squamous Cell Carcinoma Harboring <i>FGF</i> Amplifications. JCO Precision Oncology, 2018, 2, 1-7.	3.0	11
50	Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i> -Mutated Malignancies. JCO Precision Oncology, 2018, 2, 1-12.	3.0	13
51	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Journal of Clinical Oncology, 2018, 36, 1631-1641.	1.6	668
52	Prolonged Partial Response to Bevacizumab and Valproic Acid in a Patient With Glioblastoma. JCO Precision Oncology, 2018, 2, 1-6.	3.0	3
53	Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. , 2018, 6, 108.		16
54	A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemotherapy and Pharmacology, 2018, 82, 877-885.	2.3	5

#	ARTICLE	IF	CITATIONS
55	Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy. <i>Journal of Immunotherapy</i> , 2018, 41, 336-339.	2.4	7
56	Overview of precision oncology trials: challenges and opportunities. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 797-804.	3.1	31
57	Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. <i>Oncotarget</i> , 2018, 9, 28842-28848.	1.8	4
58	Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 33258-33270.	1.8	9
59	Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. <i>Oncotarget</i> , 2018, 9, 33232-33243.	1.8	26
60	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of <i>KRAS</i> Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 3657-3666.	7.0	53
61	Cardiotoxicity of Anticancer Therapies. , 2017, , 15-42.		3
62	Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine. <i>Current Problems in Cancer</i> , 2017, 41, 176-181.	2.0	16
63	Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 4-23.	2.8	1,267
64	Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. <i>Clinical Cancer Research</i> , 2017, 23, 4155-4162.	7.0	4
65	Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1-8.	3.1	5
66	Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. <i>Oncology</i> , 2017, 92, 14-20.	1.9	3
67	Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. <i>International Journal of Cancer</i> , 2017, 140, 208-215.	5.1	7
68	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. <i>Clinical Cancer Research</i> , 2017, 23, 1388-1396.	7.0	261
69	Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. <i>JCO Precision Oncology</i> , 2017, 2017, 1-18.	3.0	107
70	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. <i>JCI Insight</i> , 2017, 2, .	5.0	26
71	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent <i>KRAS</i> and <i>TP53</i> hotspot mutant cancer. <i>Oncotarget</i> , 2017, 8, 33796-33806.	1.8	5
72	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. <i>Oncotarget</i> , 2017, 8, 87163-87173.	1.8	0

#	ARTICLE	IF	CITATIONS
73	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Scientific Reports, 2016, 6, 35448.	3.3	12
74	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Medicine, 2016, 5, 3437-3444.	2.8	20
75	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Research, 2016, 76, 3690-3701.	0.9	203
76	Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2016, 77, 1097-1102.	2.3	5
77	<i>TP53</i> Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Molecular Cancer Therapeutics, 2016, 15, 2475-2485.	4.1	73
78	Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer, 2016, 122, 3401-3409.	4.1	50
79	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation. Cancer Discovery, 2016, 6, 1352-1365.	9.4	192
80	<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Molecular Cancer Therapeutics, 2016, 15, 1397-1404.	4.1	78
81	Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. Journal of the National Cancer Institute, 2016, 108, djv362.	6.3	71
82	Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates. Clinical Genitourinary Cancer, 2016, 14, e187-e193.	1.9	1
83	Strategies to optimize expedited investigational new drug safety reports. Nature Reviews Clinical Oncology, 2016, 13, 207-208.	27.6	3
84	Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2016, 77, 575-581.	2.3	7
85	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 2016, 7, 67521-67531.	1.8	44
86	Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget, 2016, 7, 23227-23238.	1.8	23
87	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget, 2016, 7, 35132-35143.	1.8	9
88	Left ventricular ejection fraction in advanced cancer patients: a valuable prognostic tool?. Future Oncology, 2015, 11, 1999-2002.	2.4	1
89	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget, 2015, 6, 12809-12821.	1.8	86
90	Precision medicine: lessons learned from the SHIVA trial. Lancet Oncology, The, 2015, 16, e579-e580.	10.7	54

#	ARTICLE	IF	CITATIONS
91	Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer, 2015, 15, 713.	2.6	43
92	Gene and cell therapy for pancreatic cancer. Expert Opinion on Biological Therapy, 2015, 15, 505-516.	3.1	18
93	Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Investigational New Drugs, 2015, 33, 215-224.	2.6	8
94	A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Investigational New Drugs, 2015, 33, 177-186.	2.6	25
95	Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2015, 75, 869-874.	2.3	26
96	Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Investigational New Drugs, 2015, 33, 621-631.	2.6	63
97	Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer, 2015, 15, 61.	2.6	25
98	Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clinical Epigenetics, 2015, 7, 29.	4.1	13
99	A Decision Support Framework for Genomically Informed Investigational Cancer Therapy. Journal of the National Cancer Institute, 2015, 107, .	6.3	168
100	Targeted therapy in cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 1113-1132.	2.3	139
101	Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Investigational New Drugs, 2015, 33, 911-920.	2.6	7
102	Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget, 2015, 6, 28453-28462.	1.8	9
103	<i>BRAF</i> mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget, 2015, 6, 26886-26894.	1.8	45
104	Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget, 2014, 5, 3012-3022.	1.8	82
105	Precision Cancer Medicine: The Future Is Now, Only Better. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 61-69.	3.8	38
106	Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 483-494.	3.3	41
107	Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents. Molecular Cancer Therapeutics, 2014, 13, 3175-3184.	4.1	31
108	Analysis of 1,115 Patients Tested for <i>MET</i> Amplification and Therapy Response in the MD Anderson Phase I Clinic. Clinical Cancer Research, 2014, 20, 6336-6345.	7.0	70

#	ARTICLE	IF	CITATIONS
109	Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic. Clinical Cancer Research, 2014, 20, 5956-5963.	7.0	10
110	Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors. Cell Reports, 2014, 6, 377-387.	6.4	210
111	Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Investigational New Drugs, 2014, 32, 279-286.	2.6	14
112	Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses. Clinical Cancer Research, 2014, 20, 4827-4836.	7.0	186
113	Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer, 2014, 120, 2164-2173.	4.1	27
114	MABp1, a first-in-class true human antibody targeting interleukin-11± in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncology, The, 2014, 15, 656-666.	10.7	178
115	A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 395-400.e1.	0.4	11
116	Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients With Advanced Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 194-203.	4.9	4
117	FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. PLoS ONE, 2014, 9, e89388.	2.5	50
118	Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience. Oncoscience, 2014, 1, 522-530.	2.2	7
119	Dual EGFR Inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience, 2014, 1, 540-549.	2.2	22
120	Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget, 2014, 5, 3029-3038.	1.8	40
121	Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget, 2014, 5, 1846-1855.	1.8	28
122	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget, 2014, 5, 2349-2354.	1.8	54
123	Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget, 2014, 5, 3871-3879.	1.8	11
124	Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget, 2014, 5, 8937-8946.	1.8	6
125	Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer. Current Pharmaceutical Biotechnology, 2014, 15, 475-485.	1.6	54
126	A pilot study of temsirolimus and body composition. Journal of Cachexia, Sarcopenia and Muscle, 2013, 4, 259-265.	7.3	25

#	ARTICLE	IF	CITATIONS
127	Anti-vascular endothelial growth factor therapy in the era of personalized medicine. Cancer Chemotherapy and Pharmacology, 2013, 72, 1-12.	2.3	17
128	Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemotherapy and Pharmacology, 2013, 71, 389-397.	2.3	13
129	Antibody-independent isolation of circulating tumor cells by continuous-flow dielectrophoresis. Biomicrofluidics, 2013, 7, 11807.	2.4	186
130	Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. Cancer Chemotherapy and Pharmacology, 2013, 72, 1265-1271.	2.3	4
131	Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. Investigational New Drugs, 2013, 31, 1505-1513.	2.6	36
132	PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials. Cancer Research, 2013, 73, 276-284.	0.9	262
133	Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 568-574.	0.4	72
134	A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemotherapy and Pharmacology, 2013, 71, 955-963.	2.3	13
135	Biomarker-Directed Therapy of Squamous Carcinomas of the Head and Neck: Targeting PI3K/PTEN/mTOR Pathway. Journal of Clinical Oncology, 2013, 31, e137-e140.	1.6	30
136	Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors. Clinical Cancer Research, 2013, 19, 4824-4831.	7.0	20
137	Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations. Molecular Cancer Therapeutics, 2013, 12, 2857-2863.	4.1	42
138	Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non-Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations. Molecular Cancer Therapeutics, 2013, 12, 2167-2175.	4.1	33
139	Strategies to Overcome Clinical, Regulatory, and Financial Challenges in the Implementation of Personalized Medicine. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 118-125.	3.8	18
140	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. , 2013, , 211-223.		10
141	Strategies to Overcome Clinical, Regulatory, and Financial Challenges in the Implementation of Personalized Medicine. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 118-125.	3.8	21
142	MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience, 2013, 1, 5-13.	2.2	25
143	Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses. Oncotarget, 2013, 4, 890-898.	1.8	42
144	Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population. Oncotarget, 2013, 4, 772-784.	1.8	16

#	ARTICLE	IF	CITATIONS
145	Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer. <i>Oncotarget</i> , 2013, 4, 118-127.	1.8	33
146	Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials. <i>Oncotarget</i> , 2013, 4, 153-162.	1.8	31
147	P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy. <i>Oncotarget</i> , 2013, 4, 705-714.	1.8	96
148	Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. <i>Hepato-Gastroenterology</i> , 2013, 60, 1611-23.	0.5	9
149	Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience. <i>Clinical Cancer Research</i> , 2012, 18, 2922-2929.	7.0	78
150	Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative. <i>Clinical Cancer Research</i> , 2012, 18, 6373-6383.	7.0	458
151	Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: The MD Anderson Cancer Center Experience. <i>Clinical Colorectal Cancer</i> , 2012, 11, 297-303.	2.3	6
152	Evaluation of the Clinical Relevance of Body Composition Parameters in Patients With Cancer Metastatic to the Liver Treated With Hepatic Arterial Infusion Chemotherapy. <i>Nutrition and Cancer</i> , 2012, 64, 206-217.	2.0	29
153	PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2012, 30, 777-782.	1.6	414
154	Lenalidomide in solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1393-1406.	2.3	28
155	Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. <i>Cancer</i> , 2012, 118, 1422-1428.	4.1	88
156	PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes. <i>Oncotarget</i> , 2012, 3, 1566-1575.	1.8	79
157	Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. <i>Hepato-Gastroenterology</i> , 2012, 59, 960-4.	0.5	2
158	Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Treated in a Phase I Clinic. <i>Oncologist</i> , 2011, 16, 327-335.	3.7	8
159	Cardiovascular Toxicity Profiles of Vascular-Disrupting Agents. <i>Oncologist</i> , 2011, 16, 1120-1130.	3.7	80
160	PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers. <i>PLoS ONE</i> , 2011, 6, e22769.	2.5	174
161	Common cardiovascular medications in cancer therapeutics. , 2011, 130, 177-190.		55
162	<i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 558-565.	4.1	311

#	ARTICLE	IF	CITATIONS
163	Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 247-253.	2.3	22
164	Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1507-1516.	2.3	5
165	Phase 1 clinical trials in 83 patients with pancreatic cancer. <i>Cancer</i> , 2011, 117, 77-85.	4.1	8
166	Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Malignancies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 997-1005.	3.6	100
167	Phase I Clinical Trial Outcomes in 93 Patients with Brain Metastases: The MD Anderson Cancer Center Experience. <i>Clinical Cancer Research</i> , 2011, 17, 4110-4118.	7.0	24
168	Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients with Advanced Malignancies: A Phase I Clinical Trial. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 209-217.	4.1	7
169	Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience. <i>Oncologist</i> , 2011, 16, 1292-1298.	3.7	60
170	Managing cardiac risk factors in oncology clinical trials. <i>Texas Heart Institute Journal</i> , 2011, 38, 266-7.	0.3	5
171	Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 235-241.	2.3	38
172	Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 1087-1093.	2.3	17
173	Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2010, 116, 880-887.	4.1	22
174	A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. <i>Cancer</i> , 2010, 116, 4086-4094.	4.1	26
175	Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?. <i>Oncologist</i> , 2010, 15, 130-141.	3.7	110
176	Salirasib in the treatment of pancreatic cancer. <i>Future Oncology</i> , 2010, 6, 885-891.	2.4	40
177	Phase I Clinical Trial of MPC-6827 (Azixa), a Microtubule Destabilizing Agent, in Patients with Advanced Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 3410-3419.	4.1	44
178	Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options. <i>Leukemia and Lymphoma</i> , 2010, 51, 1188-1199.	1.3	11
179	Farnesyltransferase inhibitors: where are we now?. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1569-1580.	4.1	39
180	Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. <i>Virology Journal</i> , 2010, 7, 256.	3.4	15

#	ARTICLE	IF	CITATIONS
181	Clinical Outcomes of Patients With Breast Cancer in a Phase I Clinic: The M. D. Anderson Cancer Center Experience. <i>Clinical Breast Cancer</i> , 2010, 10, 46-51.	2.4	10
182	Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 904-910.	1.6	203
183	A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 4769-4776.	7.0	45
184	Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center Experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4423-4432.	3.6	32
185	Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: The M. D. Anderson Cancer Center experience. <i>American Journal of Hematology</i> , 2009, 84, 408-413.	4.1	14
186	Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2009, 115, 373-380.	4.1	99
187	Survival of patients in a Phase 1 clinic. <i>Cancer</i> , 2009, 115, 1091-1099.	4.1	68
188	Treatment of fludarabine-€refractory chronic lymphocytic leukemia. <i>Cancer</i> , 2009, 115, 2824-2836.	4.1	53
189	Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 6243-6250.	1.6	79
190	Pediatric Therapy-related Myelodysplastic Syndrome/Acute Myeloid Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 803-811.	0.6	50
191	Myeloid sarcoma is associated with superior event-€free survival and overall survival compared with acute myeloid leukemia. <i>Cancer</i> , 2008, 113, 1370-1378.	4.1	165
192	The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-€risk myelodysplastic syndromes. <i>Cancer</i> , 2008, 113, 1605-1613.	4.1	102
193	Relevance of clinical trials in acute myeloid leukaemia. <i>Hematological Oncology</i> , 2008, 26, 182-183.	1.7	6
194	Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 196-203.	1.6	145
195	The Prognostic Significance of Serum Î²2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients. <i>Clinical Cancer Research</i> , 2008, 14, 721-730.	7.0	44
196	Assessment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Counts in 2,126 Patients: 20 Years of Experience at The University of Texas M.D. Anderson Cancer Center. <i>Journal of Clinical Oncology</i> , 2007, 25, 4648-4656.	1.6	80
197	Treatment of older patients with acute myeloid leukemia. <i>Aging Health</i> , 2007, 3, 663-673.	0.3	1
198	The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. <i>Leukemia and Lymphoma</i> , 2007, 48, 1931-1939.	1.3	92

#	ARTICLE	IF	CITATIONS
199	Richter's transformation in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports, 2007, 2, 265-271.	2.3	23
200	Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?. Leukemia and Lymphoma, 2006, 47, 2282-2287.	1.3	18
201	Induction mortality risk in adult acute myeloid leukemia. Leukemia and Lymphoma, 2006, 47, 1199-1200.	1.3	3
202	Richter's Transformation in Chronic Lymphocytic Leukemia. Seminars in Oncology, 2006, 33, 250-256.	2.2	67
203	Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer, 2006, 107, 125-135.	4.1	114
204	Hodgkin transformation of chronic lymphocytic leukemia. Cancer, 2006, 107, 1294-1302.	4.1	132
205	Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center. Journal of Clinical Oncology, 2006, 24, 1582-1589.	1.6	192
206	Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell Transplantation. Journal of Clinical Oncology, 2006, 24, 2343-2351.	1.6	250
207	Myeloid Sarcoma Involving the Gynecologic Tract. American Journal of Clinical Pathology, 2006, 125, 783-790.	0.7	66
208	Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leukemia and Lymphoma, 2006, 47, 1062-1068.	1.3	57
209	Epstein-Barr virus in patients with chronic lymphocytic leukemia: A pilot study. Leukemia and Lymphoma, 2006, 47, 827-836.	1.3	36
210	Combination of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Richter's Syndrome and Fludarabine-Refractory Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2825-2825.	1.4	2
211	Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. Journal of Nuclear Medicine, 2006, 47, 1267-73.	5.0	129
212	Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood, 2005, 105, 1366-1367.	1.4	27
213	Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leukemia Research, 2005, 29, 649-652.	0.8	17
214	The role of gemtuzumab ozogamicin in acute leukaemia therapy. British Journal of Haematology, 2005, 132, 051220022257010.	2.5	60
215	Richter syndrome. Cancer, 2005, 103, 216-228.	4.1	254
216	Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer, 2005, 104, 345-353.	4.1	23

#	ARTICLE	IF	CITATIONS
217	Phase II study of pentostatin in advanced T-cell lymphoid malignancies. <i>Cancer</i> , 2004, 100, 342-349.	4.1	75
218	Activity of interferon- γ and isotretinoin in patients with advanced, refractory lymphoid malignancies. <i>Cancer</i> , 2004, 100, 574-580.	4.1	27
219	Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. <i>Cancer</i> , 2004, 100, 2195-2200.	4.1	37
220	Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2004, 100, 2583-2591.	4.1	40
221	Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. <i>Leukemia Research</i> , 2004, 28, 657-660.	0.8	10
222	Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. <i>Leukemia Research</i> , 2004, 28, 991-994.	0.8	32
223	Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 200-204.	1.2	29
224	Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 229-234.	2.3	10
225	Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 449-452.	2.3	31
226	Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. <i>Cancer</i> , 2003, 97, 1711-1720.	4.1	110
227	Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. <i>Cancer</i> , 2003, 97, 1721-1731.	4.1	40
228	Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF α levels during treatment. <i>Leukemia Research</i> , 2003, 27, 375-380.	0.8	59
229	Anti-B4 Blocked Ricin Post Chemotherapy in Patients with Chronic Lymphocytic Leukemia-Long-term Follow-up of a Monoclonal Antibody-based Approach to Residual Disease. <i>Leukemia and Lymphoma</i> , 2003, 44, 1719-1725.	1.3	17
230	Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 437-448.	2.4	65
231	TNF- α targeted therapeutic approaches in patients with hematologic malignancies. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 277-286.	2.4	32
232	Essential Thrombocythemia (ET): Moving from Palliation to Cure. <i>Hematology</i> , 2002, 7, 315-323.	1.5	5
233	Quantitative Real-Time Polymerase Chain Reaction for Detection of Circulating Cells with T(14;18) in Volunteer Blood Donors and Patients with Follicular Lymphoma. <i>Leukemia and Lymphoma</i> , 2002, 43, 1589-1598.	1.3	14
234	Phase II Study of Fludarabine, Cytarabine (Ara-C), Cyclophosphamide, Cisplatin and GM-CSF (FACPGM) in Patients With Richter's Syndrome or Refractory Lymphoproliferative Disorders. <i>Leukemia and Lymphoma</i> , 2002, 43, 767-772.	1.3	58

#	ARTICLE	IF	CITATIONS
235	Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. <i>Blood</i> , 2002, 100, 4351-4357.	1.4	59
236	Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. <i>Seminars in Oncology</i> , 2002, 29, 48-55.	2.2	14
237	Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 237-242.	2.3	22
238	Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 497-500.	2.3	64
239	Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. <i>Leukemia Research</i> , 2002, 26, 143-154.	0.8	33
240	Hodgkin's Disease in Patients Infected with Human Immunodeficiency Virus: Frequency, Presentation and Clinical Outcome. <i>Leukemia and Lymphoma</i> , 2001, 41, 535-544.	1.3	14